- Home
- ECOR vs GANX Comparison
ECOR vs GANX Comparison
Compare ECOR & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECOR | GANX |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.0M | 78.5M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ECOR | GANX |
|---|---|---|
| Price | $6.16 | $1.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $18.00 | $7.50 |
| AVG Volume (30 Days) | 81.0K | ★ 792.5K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,032,000.00 | $55,180.00 |
| Revenue This Year | $33.60 | N/A |
| Revenue Next Year | $30.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 27.20 | N/A |
| 52 Week Low | $4.16 | $1.41 |
| 52 Week High | $10.50 | $4.34 |
Technical Indicators
Market Signals| Indicator | ECOR | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 38.61 | 48.92 |
| Support Level | $5.69 | $1.66 |
| Resistance Level | $7.35 | $2.09 |
| Average True Range (ATR) | 0.66 | 0.11 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 17.60 | 60.00 |
Price Performance
Historical ComparisonAbout ECOR electroCore Inc.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.